Alexion Pharma (ALXN): Products Unimpaired - Leerink

November 10, 2016 8:26 AM EST
Get Alerts ALXN Hot Sheet
Price: $125.62 --0%

Rating Summary:
    21 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 3 | New: 1
Trade ALXN Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) after the company filed a Form 12b-25 Notification of Late Filing for their Q3 2016 10-Q.

The company disclosed that their board’s Audit and Finance Committee is investigating alleged fraudulent sales practices for Soliris based on allegations made by a former employee. ALXN did not file the third quarter 2016 10-Q by yesterday’s deadline, and has offered no assurance that their quarterly accounts will be filed within the SEC’s five day grace period after the non-timely (NT) notice. From our conversation last night with management, it indeed seems likely that the resolution of this investigation, and the clarification of the company’s re-statements, if needed, will take potentially weeks rather than days.

No change to the price target of $211.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $127.16 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment